Companies have Shifted Focus to Mergers and Acquisitions to Acquire More Production Capabilities

DUBLIN, 9 Dec 2021 / PRNewswire / – Global Market Report 2021: COVID-19 Growth and Change to 2030 has been added to ResearchAndMarkets.com’s offering.

The global market for monoclonal biosimilars is expected to be driven by $ 3.52 billion in 2020 to $ 4.33 billion in 2021 with a compound annual growth rate (CAGR) of 23%. The market is expected to reach $ 10.92 billion in 2025 at a CAGR of 26%.

The main players in the biosimilar monoclonal antibody market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics and Intas Pharmaceuticals Limited.

Biosimilar Monoclonal Antibody Market consists of the sale of Biosimilar Monoclonal Antibodies and related services by companies (organizations, sole proprietorships, and partnerships) that manufacture biosimilar monoclonal antibodies that are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis and autoimmune diseases can be used.

Biosimilar monoclonal antibodies are very similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety and efficacy and are used to strengthen immunity by identifying and neutralizing foreign objects. The market consists of revenue generated by biosimilar monoclonal antibody companies from the sale of these products.

The Biosimilar Monoclonal Antibody Market covered in this report is segmented into Synthetic Chemicals, Biopharmaceuticals, etc., and application in Chronic and Autoimmune Diseases, Oncology, etc. by type.

Tight biosimilar approval regulations are expected to hinder the growth of the biosimilar monoclonal antibody market. The governments of different regions have different rules regarding the manufacture and use of biosimilars. In addition, issues such as patent infringement or contractual issues prevent biosimilars manufacturers from commercializing the government-approved biosimilars.

The US Food and Drug Administration requires dual regulatory approval for biosimilars, which limits the use of biosimilars as interchangeable drugs to biologics Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics.

In February 2019, of the total of 17 approved biosimilars, only 7 biosimilars, including 4 biologics of origin, were able to enter the US market. The strict government guidelines for approving these drugs are negatively affecting manufacturers in the biosimilar monoclonal antibody market.

In May 2020, AbbVie, a US biopharmaceutical company, bought Allergan for an amount of $ 63 million. This transaction expands and diversifies AbbVie’s revenue base and helps it maintain its leadership position in biosimilar monoclonal antibodies. Allergan is a Ireland-based pharmaceutical company that manufactures, develops, and markets drugs, biosimilars, medical devices, ophthalmology, and others.

The prevalence of chronic diseases is expected to fuel the market for biosimilar monoclonal antibodies. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune diseases, and rheumatoid arthritis. Biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab and rituximab are used in cancer treatment. In addition, the incidence of cancer is increasing every year. Therefore, the prevalence of chronic diseases, including cancer, is expected to fuel the market for biosimilar monoclonal antibodies.

The focus of many companies in the biosimilar monoclonal antibody market has shifted to mergers and acquisitions to acquire more manufacturing capacity. Large, high-quality manufacturers set up joint ventures or buy small or medium-sized businesses in order to acquire new skills or gain access to new markets.

Key topics covered:

1. Summary

2. Market Characteristics for Biosimilar Monoclonal Antibodies

3. Biosimilar Monoclonal Antibody Market Trends and Strategies

4. Effects of COVID-19 on biosimilar monoclonal antibodies

5. Biosimilar Monoclonal Antibodies market size and growth
5.1. Global Historic Biosimilar Monoclonal Antibody Market, 2015-2020, $ Billion
5.1.1. Driver of the market
5.1.2. Restrictions in the market
5.2. Global Biosimilar Antibody Monoclonal Prediction Market, 2020-2025F, 2030F, Billion US Dollars
5.2.1. Driver of the market
5.2.2. Restrictions in the market

6. Biosimilar Monoclonal Antibodies Market Segmentation
6.1. Global Biosimilar Monoclonal Antibody Market, Segmentation By Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

  • Synthetic chemicals
  • Biopharmaceuticals
  • Other

6.2. Global Biosimilar Monoclonal Antibody Market, Segmentation By Application, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

  • Chronic and autoimmune diseases
  • oncology
  • Other

6.3. Global Biosimilar Monoclonal Antibody Market, Segmentation By Compound, History And Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab

7. Regional and country analysis of the market for biosimilar monoclonal antibodies
7.1. Global Biosimilar Monoclonal Antibody Market Split By Region, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion $
7.2. Global Biosimilar Monoclonal Antibody Market Split By Country, Historians & Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

Mentioned companies

  • Pfizer
  • Novartis
  • Allergan
  • Coherus BioSciences
  • Biocon
  • Amgen
  • Boehringer Ingelheim
  • Celltrion
  • BioXpress Therapeutics
  • Intas Pharmaceuticals Limited
  • Genor BioPharma Co. Ltd
  • BIOCAD
  • Dr. Reddys Laboratories Ltd
  • 3SBio
  • Trust in Life Sciences
  • Hisun Pharma
  • Celgen Biopharma
  • Torrent Medicines
  • Cadila Health Care

Please visit https://www.researchandmarkets.com/r/9z80nq for more information on this report

Media contact:

Research and Markets
Laura wood, Senior manager
[email protected]

For EST office hours, call + 1-917-300-0470. on
For US / CAN toll free call + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900. on

US Fax: 646-607-1907
Fax (outside the US): + 353-1-481-1716

SOURCE Research and Markets

similar links

http://www.researchandmarkets.com

Comments are closed.